This new Ebola vaccine has been shown to be '100 percent effective'
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
You are now subscribed
Your newsletter sign-up was successful
The results are in from drug giant Merck's most recent trial of a vaccine for Ebola — and they look pretty good:
The vaccine was 100 percent effective when it was tested on more than 4,000 people who were in close contact with Ebola patients in the African nation of Guinea, the World Health Organization said, citing a study published today in the Lancet medical journal. The trial of the vaccine, called Ebola ca suffit — "Ebola, that's enough" in French — began on March 23. [Bloomberg]
A panel overseeing the trial says a late-stage trial of the vaccine should proceed.
The Ebola outbreak that gripped West Africa last year — killing 11,000 people — has subsided, but the virus is stubbornly sticking around. New confirmed cases were reported this week.
Article continues belowThe Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Ryu Spaeth is deputy editor at TheWeek.com. Follow him on Twitter.